KR20010033823A - 아릴 융합된 아자폴리사이클릭 화합물 - Google Patents
아릴 융합된 아자폴리사이클릭 화합물 Download PDFInfo
- Publication number
- KR20010033823A KR20010033823A KR1020007007379A KR20007007379A KR20010033823A KR 20010033823 A KR20010033823 A KR 20010033823A KR 1020007007379 A KR1020007007379 A KR 1020007007379A KR 20007007379 A KR20007007379 A KR 20007007379A KR 20010033823 A KR20010033823 A KR 20010033823A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- formula
- compound
- disease
- dodeca
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/24—Camphidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
Abstract
Description
Claims (14)
- 하기 화학식 I의 화합물 또는 그의 약학적으로 허용가능한 염:화학식 I상기 식에서,R1은 수소, (C1-C6)알킬, 비공액 (C3-C6)알케닐, XC(=O)R13또는 -CH2CH2-O-(C1-C4)알킬이고;R2및 R3은 수소, (C2-C6)알케닐, (C2-C6)알키닐, 히드록시, 니트로, 아미노, 할로, 시아노, -SOq(C1-C6)알킬(여기서, q는 0, 1 또는 2이다), (C1-C6)알킬아미노-, [(C1-C6)알킬]2아미노-, -CO2R4, -CONR5R6, -SO2NR7R8, -C(=O)R13, -XC(=O)R13, 아릴-(C0-C3)알킬- 또는 아릴-(C0-C3)알킬-O-(여기서, 아릴은 페닐 및 나프틸로부터 선택된다), 헤테로아릴-(C0-C3)알킬- 또는 헤테로아릴-(C0-C3)알킬-O-(여기서, 헤테로아릴은 산소, 질소 및 황으로부터 선택된 1 내지 4개의 헤테로 원자를 함유하는 5 내지 7원 방향족 고리로부터 선택된다), 및 X2(C0-C6)알콕시-(C0-C6)알킬-[여기서, X2는 존재하지 않거나, (C1-C6)알킬아미노- 또는 [(C1-C6)알킬]2아미노-이고, X2(C0-C6)알콕시-(C0-C6)알킬-중 (C0-C6)알콕시-(C0-C6)알킬- 잔기는 하나 이상의 탄소 원자를 함유하고, (C0-C6)알콕시-(C0-C6)알킬-잔기중 탄소 원자 1 내지 3개는 산소, 질소 또는 황 원자에 의해 임의로 치환될 수 있으나, 단 임의의 2개의 상기 헤테로 원자는 둘 이상의 탄소 원자에 의해 분리되어야 하고, (C0-C6)알콕시-(C0-C6)알킬-중 임의의 알킬 잔기는 2 내지 7개의 불소 원자에 의해 임의로 치환될 수 있다]로부터 독립적으로 선택되고, 이때 상기 아릴-(C0-C3)알킬- 및 헤테로아릴-(C0-C3)알킬-의 각 알킬 잔기의 탄소 원자중 하나는 산소, 질소 또는 황 원자에 의해 임의로 치환될 수 있고, 상기의 각 아릴 및 헤테로아릴 기는 1 내지 7개의 불소 원자로 임의로 치환된 (C1-C6)알킬, 2 내지 7개의 불소 원자로 임의로 치환된 (C1-C6)알콕시, 클로로, 플루오로, 브로모 및 요오도로부터 선택된 할로, (C2-C6)알케닐, (C2-C6)알키닐, 히드록시, 니트로, 시아노, 아미노, (C1-C6)알킬아미노-, [(C1-C6)알킬]2아미노-, -CO2R4, -CONR5R6, -SO2NR7R8, -C(=O)R13및 -XC(=O)R13으로부터 독립적으로 선택된 하나 이상의 치환기, 바람직하게는 0 내지 2개의 치환기에 의해 임의로 치환될 수 있으며; 또는R2및 R3은 이들이 결합되어 있는 탄소 원자와 함께 포화되거나 불포화될 수 있는 4 내지 7원의 모노사이클릭 또는 10 내지 14원의 바이사이클릭 탄소환 고리를 형성하고, 여기서 상기 모노사이클릭 고리중 융합되지 않은 탄소 원자중 1 내지 3개, 및 화학식 I에 나타낸 벤조 고리의 일부가 아닌 상기 바이사이클릭 고리의 탄소 원자중 1 내지 5개는 질소, 산소 또는 황에 의해 임의로 및 독립적으로 치환될 수 있고, 상기 모노사이클릭 및 바이사이클릭 고리는 1 내지 7개의 불소 원자에 의해 임의로 치환된 (C1-C6)알킬, 1 내지 7개의 불소 원자에 의해 임의로 치환된 (C1-C6)알콕시, 니트로, 시아노, 할로, (C2-C6)알케닐, (C2-C6)알키닐, 히드록시, 아미노, (C1-C6)알킬아미노, [(C1-C6)알킬]2아미노, -CO2R4, -CONR5R6, -SO2NR7R8, -C(=O)R13및 -XC(=O)R13으로부터 독립적으로 선택된 치환기에 의해, 모노사이클릭 고리는 하나 이상, 바람직하게는 0 내지 2개의 치환기로 치환되고, 바이사이클릭 고리는 0 내지 3개의 치환기로 치환될 수 있고;각각의 R4, R5, R6, R7, R8및 R13은 수소 및 (C1-C6)알킬로부터 독립적으로 선택되거나, R5및 R6또는 R7및 R8은 이들이 결합된 질소 원자와 함께 피롤리딘, 피페리딘, 모르폴린, 아제티딘, 피페리진, N(C1-C6)알킬피페리진 또는 티오모르폴린 고리, 또는 고리의 황 원자가 설폭사이드 또는 설폰으로 치환된 티오모르폴린 고리를 형성하고;각각의 X는 독립적으로 (C1-C6)알킬렌이나;단, (a) R1, R2및 R3중 하나 이상은 수소가 아니어야 하고, (b) R2및 R3이 둘 다 수소인 경우 R1은 수소 또는 메틸일 수 없다.
- 제 1 항에 있어서,R2및 R3이 화학식 I의 벤조 고리와 함께 하기 화학식으로부터 선택된 바이사이클릭 고리 시스템을 형성하는 화합물:상기 식에서,R10및 R17은 (C0-C6)알콕시-(C0-C6)알킬-(여기서, 탄소 원자의 총 수는 6 이하이고 임의의 알킬 잔기는 1 내지 7개의 불소 원자에 의해 임의로 치환될 수 있다), 니트로, 시아노, 할로, 아미노, (C1-C6)알킬아미노-, [(C1-C6)알킬]2아미노-, -CO2R4, -CONR5R6, -SO2NR7R8, -C(=O)R13, -XC(=O)R13, 페닐 및 모노사이클릭 헤테로아릴(여기서, 헤테로아릴은 산소, 질소 및 황으로부터 선택된 1 내지 4개의 헤테로 원자를 함유하는 5 내지 7원 방향족 고리로부터 선택된다)로부터 독립적으로 선택된다.
- 제 1 항에 있어서,R2및 R3이 화학식 I의 벤조 고리와 함께 바이사이클릭 또는 트리사이클릭 고리 시스템을 형성하지 않는 화합물.
- 제 1 항에 있어서,R2및 R3중 하나 또는 둘 다가 -C(=O)R13이고, 이 때 R13이 (C1-C6)알킬인 화합물.
- 제 1 항에 있어서,R2및 R3중 하나가 -COR13이고, 이 때 R13이 1 내지 7개의 불소 원자로 임의로 치환된 (C1-C6)알킬 또는 (C1-C3)알킬인 화합물.
- 제 1 항에 있어서,R2및 R3중 하나가 CF3, 플루오로, 시아노 또는 C2F5인 화합물.
- 니코틴 탐닉을 감소시키거나 담배 사용을 중단하거나 줄이는데 도움을 주는 효과적인 양의 제 1 항에 따른 화합물 및 약학적으로 허용가능한 담체를 포함하는, 포유동물에서의 니코틴 탐닉을 감소시키거나 담배 사용을 중단하거나 줄이는데 도움을 주기 위해 사용하기 위한 약학 조성물.
- 니코틴 탐닉을 감소시키거나 담배 사용을 중단하거나 줄이는데 도움을 주는 효과적인 양의 제 1 항에 따른 화합물을 포유동물에게 투여함을 포함하는, 상기 포유동물에서의 니코틴 탐닉을 감소시키거나 담배 사용을 중단하거나 줄이는데 도움을 주는 방법.
- 포유동물에서의 궤양성 대장염, 괴저성 농피증 및 크론병(Crohn's disease)을 포함하나 이에 한정되지 않는 염증성 장 질환; 과민성 대장 증후군, 경련성 디스토니아, 만성통, 급성통, 복강 스프루우(sprue), 파우치티스(pouchitis), 혈관수축, 불안, 공황 장애, 우울증, 양극성 장애, 자폐증, 불면증, 시차로 인한 피로, 근위축성 측삭 경화증(ALS), 인지 기능부전, 고혈압, 병적기아, 식욕부진, 비만증, 심장성 부정맥, 위산 분비과다, 궤양, 크롬친화성세포종, 진행성 근육상 마비; 니코틴(및/또는 담배 제품), 알콜, 벤조디아제핀, 바르비투르산염, 아편양제제 또는 코카인에 대한 의존증 또는 탐닉으로부터 선택된 화학물질 의존증 및 탐닉; 두통, 발작, 외상후 뇌손상(TBI), 정신병, 헌팅톤 무도병(Huntington's Chorea), 만기의 이상운동증, 운동과다증, 실독증, 정신분열증, 다중경색성 치매, 연령 관련 인지 감퇴, 무-소발작 간질을 비롯한 간질, 알츠하이머(Alzheimer's) 유형의 노인성 치매(AD), 파킨슨병(Parkinson's disease: PD), 주의력 결핍 과잉행동 장애(ADHD) 및 투렛 증후군으로부터 선택된 장애 또는 증상을 치료하는데 효과적인 양의 제 1 항에 따른 화합물 및 약학적으로 허용가능한 담체를 포함하는, 상기 장애 또는 증상을 치료하기 위한 약학 조성물.
- 포유동물에서의 궤양성 대장염, 괴저성 농피증 및 크론병을 포함하나 이에 한정되지 않는 염증성 장 질환; 과민성 대장 증후군, 경련성 디스토니아, 만성통, 급성통, 복강 스프루우, 파우치티스, 혈관수축, 불안, 공황 장애, 우울증, 양극성 장애, 자폐증, 불면증, 시차로 인한 피로, 근위축성 측삭 경화증(ALS), 인지 기능부전, 고혈압, 병적기아, 식욕부진, 비만증, 심장성 부정맥, 위산 분비과다, 궤양, 크롬친화성세포종, 진행성 근육상 마비; 니코틴(및/또는 담배 제품), 알콜, 벤조디아제핀, 바르비투르산염, 아편양제제 또는 코카인에 대한 의존증 또는 탐닉으로부터 선택된 화학물질 의존증 및 탐닉; 두통, 발작, 외상후 뇌손상(TBI), 정신병, 헌팅톤 무도병, 만기의 이상운동증, 운동과다증, 실독증, 정신분열증, 다중경색성 치매, 연령 관련 인지 감퇴, 무-소발작 간질을 비롯한 간질, 알츠하이머 유형의 노인성 치매(AD), 파킨슨병(PD), 주의력 결핍 과잉행동 장애(ADHD) 및 투렛 증후군으로부터 선택된 장애 또는 증상을 치료하는데 효과적인 양의 제 1 항에 따른 화합물을 이러한 치료를 필요로 하는 포유동물에게 투여함을 포함하는, 상기 장애 또는 증상을 치료하는 방법.
- 하기 화학식 I-1의 화합물:화학식 I-1상기 식에서,P는 수소, 메틸, COOR16[여기서, R16은 (C1-C6)알킬, 알릴 또는 2,2,2-트리클로로에틸이다], -C(=O)NR5R6(여기서, R5및 R6은 상기 화학식 I에 정의된 바와 같다), -C(=O)H, -C(=O)(C1-C6)알킬(여기서, 알킬 잔기는 1 내지 3개의 할로 원자, 바람직하게는 1 내지 3개의 플루오로 또는 클로로 원자로 임의로 치환될 수 있다), 벤질, t-부톡시카보닐(t-Boc) 또는 트리플루오로아세틸이고;R14및 R15는 수소, 1 내지 7개의 불소 원자에 의해 임의로 치환된 (C1-C6)알킬, -(C=O)(C1-C6)알킬, 시아노, 히드록시, 니트로, 아미노, -O(C1-C6)알킬 및 할로로부터 독립적으로 선택되나, 단, P가 수소 또는 메틸인 경우 R14및 R15는 둘 다 수소일 수 없다.
- 니코틴 탐닉을 감소시키거나 담배 사용을 중단하거나 줄이는데 도움을 주는 효과적인 양의 하기 화학식 I-2의 화합물 또는 그의 약학적으로 허용가능한 염을 포함하는 화합물을 포유동물에게 투여함을 포함하는, 포유동물에서 니코틴 탐닉을 감소시키거나 담배 사용을 중단하거나 줄이는데 도움을 주는 방법:화학식 I-2
- 포유동물에서 궤양성 대장염, 괴저성 농피증 및 크론병을 포함하나 이에 한정되지 않는 염증성 장 질환; 과민성 대장 증후군, 경련성 디스토니아, 만성통, 급성통, 복강 스프루우, 파우치티스, 혈관수축, 불안, 공황 장애, 우울증, 양극성 장애, 자폐증, 불면증, 시차로 인한 피로, 근위축성 측삭 경화증(ALS), 인지 기능부전, 고혈압, 병적기아, 식욕부진, 비만증, 심장성 부정맥, 위산 분비과다, 궤양, 크롬친화성세포종, 진행성 근육상 마비; 니코틴(및/또는 담배 제품), 알콜, 벤조디아제핀, 바르비투르산염, 아편양제제 또는 코카인에 대한 의존증 또는 탐닉으로부터 선택된 화학물질 의존증 및 탐닉; 두통, 발작, 외상후 뇌손상(TBI), 정신병, 헌팅톤 무도병, 만기의 이상운동증, 운동과다증, 실독증, 정신분열증, 다중경색성 치매, 연령 관련 인지 감퇴, 무-소발작 간질을 비롯한 간질, 알츠하이머 유형의 노인성 치매(AD), 파킨슨병(PD), 주의력 결핍 과잉행동 장애(ADHD) 및 투렛 증후군으로부터 선택된 장애 또는 증상을 치료하기에 효과적인 양의 하기 화학식 I-2의 화합물 또는 그의 약학적으로 허용가능한 염을 이러한 치료를 필요로 하는 포유동물에게 투여함을 포함하는, 포유동물에서의 상기 장애 또는 증상을 치료하기 위한 방법:화학식 I-2
- 하기 화학식 I-3의 화합물:화학식 I-3상기 식에서,R2및 R3은 제 1 항에 정의된 바와 같고;P'는 COOR16[여기서, R16은 알릴, 2,2,2-트리클로로에틸 또는 (C1-C6)알킬이다], -C(=O)NR5R6(여기서, R5및 R6은 제 2 항에 정의된 바와 같다), -C(=O)H, -C(=O)(C1-C6)알킬(여기서, 알킬 잔기는 1 내지 3개의 할로 원자, 바람직하게는 1 내지 3개의 플루오로 또는 클로로 원자로 임의로 치환될 수 있다), 벤질 또는 t-부톡시카보닐(t-Boc)이다.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7024597P | 1997-12-31 | 1997-12-31 | |
US60/070,245 | 1997-12-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010033823A true KR20010033823A (ko) | 2001-04-25 |
KR100408138B1 KR100408138B1 (ko) | 2003-12-01 |
Family
ID=22094096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-7007379A KR100408138B1 (ko) | 1997-12-31 | 1998-11-13 | 아릴 융합된 아자폴리사이클릭 화합물 |
Country Status (52)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101109389B1 (ko) * | 2010-04-30 | 2012-01-30 | 삼성전기주식회사 | 인쇄회로기판 및 그 제조방법 |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
SI1044189T2 (sl) * | 1997-12-31 | 2015-05-29 | Pfizer Products Inc. | Z arilom kondenzirane azapoliciklične spojine |
DE60040293D1 (de) | 1999-07-28 | 2008-10-30 | Univ R | Verwendung von nikotin in der angiogenese und der vaskulogenese |
US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
US20020010192A1 (en) * | 2000-06-02 | 2002-01-24 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
US20020016334A1 (en) * | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
DE60225433T2 (de) * | 2001-04-20 | 2008-06-12 | Pfizer Products Inc., Groton | Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen |
IL157933A0 (en) | 2001-05-14 | 2004-03-28 | Pfizer Prod Inc | Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9] -hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
CN1509288A (zh) | 2001-05-14 | 2004-06-30 | �Ʒ� | 5,8,14-三氮杂四环[10.3.1.02,11.04,9]-十六-2(11),3,5,7,9-五烯的柠檬酸盐 |
RU2004116311A (ru) * | 2001-11-29 | 2005-03-27 | Пфайзер Продактс Инк. (Us) | Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции |
DE60228478D1 (de) | 2001-11-30 | 2008-10-02 | Pfizer Prod Inc | Aryl-annellierte azapolyzyklische verbindungen |
CN1864663A (zh) * | 2001-11-30 | 2006-11-22 | 辉瑞产品公司 | 5,7,14-三氮杂四环[10.3.1.0(2,11).0(4,9)]-十六碳-2(11)3,5,7,9-五烯的药物组合物 |
US7320788B2 (en) * | 2002-02-14 | 2008-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for Celiac Sprue |
US8143210B2 (en) | 2002-02-14 | 2012-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
EP1572127B2 (en) | 2002-02-14 | 2014-10-29 | The Board of Trustees of the Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
US7462688B2 (en) * | 2002-05-14 | 2008-12-09 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for diagnostic and therapeutic methods for celiac sprue |
US7202216B2 (en) * | 2002-05-14 | 2007-04-10 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for celiac sprue |
US7265093B2 (en) * | 2002-05-14 | 2007-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for Celiac Sprue |
US7605150B2 (en) * | 2002-05-14 | 2009-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for Celiac Sprue |
CA2502443A1 (en) * | 2002-11-20 | 2004-06-03 | Pfizer Products Inc. | A method for preparing indan-1,3-dicarboxylic acid |
EP1563300B1 (en) * | 2002-11-20 | 2012-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic method for celiac sprue |
WO2004048318A1 (en) * | 2002-11-25 | 2004-06-10 | Pfizer Products Inc. | Improved process for the preparation of 1,3-substituted indenes |
US20070066827A1 (en) * | 2003-01-15 | 2007-03-22 | Pfizer Inc. | Process for the preparation of aryl fused polycyclic lactams |
US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
US20040224963A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
CA2525874C (en) * | 2003-05-20 | 2007-11-27 | Pfizer Products Inc. | Pharmaceutical compositions of varenicline |
CA2527337A1 (en) * | 2003-06-04 | 2004-12-16 | Pfizer Products Inc. | Preparation of substituted quinoxalines from the dianline with 2,3-dihydroxy-1,4-dioxane |
CA2533100A1 (en) * | 2003-07-21 | 2005-01-27 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
WO2005007655A1 (en) | 2003-07-21 | 2005-01-27 | Pfizer Products Inc. | Nicotine addiction reducing heteroaryl fused azapolycyclic compounds |
US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
US20050043406A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
US7579313B2 (en) * | 2003-11-18 | 2009-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | Transglutaminase inhibitors and methods of use thereof |
US7534426B2 (en) * | 2004-04-26 | 2009-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Glutenase enzyme assays |
US7628985B2 (en) * | 2004-04-26 | 2009-12-08 | The Board Of Regents Of The Leland Stanford Junior University | Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis |
US7563864B2 (en) * | 2004-04-26 | 2009-07-21 | Celiac Sprue Research Foundation | Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten |
WO2006006071A1 (en) * | 2004-07-07 | 2006-01-19 | Pfizer Products Inc. | Resolution of an aryl-fused azapolycyclic compound |
US7766018B2 (en) * | 2004-09-30 | 2010-08-03 | Smoke-Break, Inc. | Device and composition for reducing the incidence of tobacco smoking |
DE602006003320D1 (de) * | 2005-02-24 | 2008-12-04 | Pfizer Prod Inc | Herstellung eines substituierten chinoxalins von hoher reinheit |
US20060211649A1 (en) * | 2005-03-21 | 2006-09-21 | Eric Marchewitz | Use of cytisine for enhancing physical performance |
US20100048713A1 (en) * | 2006-01-06 | 2010-02-25 | Aarhus Universitet | Compounds acting on the serotonin transporter |
EP2004186A2 (en) * | 2006-03-27 | 2008-12-24 | Pfizer Products Inc. | Varenicline standards and impurity controls |
CA2650211A1 (en) * | 2006-04-24 | 2007-11-01 | Prizer Products Inc. | Asymmetric membranes for drug delivery devices |
WO2008028903A2 (en) | 2006-09-04 | 2008-03-13 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
KR20090086071A (ko) * | 2006-11-09 | 2009-08-10 | 화이자 프로덕츠 인코포레이티드 | 니코틴 중간체의 다형체 |
MX2009009780A (es) * | 2007-03-16 | 2010-05-20 | Univ Leland Stanford Junior | Terapia de enzima de combinacion para la digestion de gluten dietetico. |
WO2009034431A2 (en) | 2007-09-10 | 2009-03-19 | Pfizer Inc. | Controlled-release dosage forms for varenicline |
WO2009101185A2 (en) * | 2008-02-15 | 2009-08-20 | Medichem, S.A. | A NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3] BENZAZEPINE DERIVATIVE |
US20090215787A1 (en) * | 2008-02-22 | 2009-08-27 | Mai De Ltd. | Preparations of new polymorphic forms of varenicline tartrate |
US9463190B2 (en) * | 2008-03-31 | 2016-10-11 | University Of South Florida | Methods of treating disease-induced ataxia and non-ataxic imbalance |
CA2709774C (en) * | 2008-05-22 | 2012-10-02 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
US20090318460A1 (en) * | 2008-05-26 | 2009-12-24 | Glenmark | Amorphous varenicline tartrate and process for the preparation thereof |
WO2009155403A2 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of varenicline and intermediates thereof |
US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
US8314235B2 (en) * | 2008-09-01 | 2012-11-20 | Actavis Group Ptc Ehf | Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof |
EP2204369A1 (en) | 2008-12-22 | 2010-07-07 | Medichem, S.A. | Process for preparing varenicline and intermediates for use therein |
WO2010093425A1 (en) | 2009-02-11 | 2010-08-19 | Sepracor Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
US20120093887A1 (en) | 2009-06-10 | 2012-04-19 | Actavis Group Ptc Ehf | Amorphous varenicline tartrate co-precipitates |
EP2438054A1 (en) * | 2009-06-22 | 2012-04-11 | Teva Pharmaceutical Industries Ltd. | Solid states forms of varenicline salts and processes for preparation thereof |
CA2772525A1 (en) * | 2009-09-11 | 2011-03-17 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
AU2011225747A1 (en) | 2010-03-09 | 2012-09-27 | Actavis Group Ptc Ehf | Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity |
WO2011140431A1 (en) | 2010-05-06 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Varenicline salts and crystal forms thereof |
US20120004239A1 (en) | 2010-06-11 | 2012-01-05 | Medichem, S.A. | Process for Preparing Quinoxaline Derivatives |
KR20140027939A (ko) | 2011-06-30 | 2014-03-07 | 도레이 카부시키가이샤 | 지양제 |
ITMI20111413A1 (it) | 2011-07-28 | 2013-01-29 | Dipharma Francis Srl | Procedimento per la preparazione di vareniclina |
ES2426517B1 (es) | 2012-04-20 | 2014-05-14 | Genetracer Biotech S.L | Método para predecir la seguridad de un tratamiento farmacológico |
ES2426838B1 (es) | 2012-04-20 | 2014-05-07 | Genetracer Biotech S.L | Método para predecir el éxito en el abandono del consumo de tabaco en respuesta a un tratamiento farmacológico |
CN103570502A (zh) * | 2012-07-18 | 2014-02-12 | 上海科胜药物研发有限公司 | 一种伐伦克林中间体的制备方法 |
US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
CN103992272B (zh) * | 2014-06-09 | 2016-05-11 | 安徽省逸欣铭医药科技有限公司 | 一种盐酸喷他佐辛酯、其制备方法及其用途 |
KR20160126697A (ko) | 2015-04-24 | 2016-11-02 | 한미정밀화학주식회사 | 신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물 |
KR20160143407A (ko) | 2015-06-05 | 2016-12-14 | 한미정밀화학주식회사 | 신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법 |
KR101724301B1 (ko) | 2016-11-22 | 2017-04-10 | 주식회사 한서켐 | 바레니클린 살리실산염의 i형 결정 및 그 제조방법 |
CN106674194B (zh) * | 2016-12-14 | 2019-03-05 | 山东省联合农药工业有限公司 | 一种结构新颖的烟碱类杀虫剂及其制备方法和用途 |
JP7137850B2 (ja) | 2017-03-03 | 2022-09-15 | シーティーシー バイオ インク | バレニクリンまたはその薬学的に許容可能な塩の包接複合体を含む口腔投与用製剤 |
KR102463733B1 (ko) | 2017-06-30 | 2022-11-04 | 한미약품 주식회사 | 함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물 |
WO2018154395A2 (en) | 2018-06-11 | 2018-08-30 | Alvogen Malta Operations (Row) Ltd | Controlled release pharmaceutical composition of varenicline |
KR20200034293A (ko) | 2018-09-21 | 2020-03-31 | 한미약품 주식회사 | 제어 방출용 바레니클린 제제 |
TW202206078A (zh) | 2020-04-28 | 2022-02-16 | 美商奧伊斯特普安生物製藥公司 | 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染 |
CN113956255A (zh) * | 2020-07-20 | 2022-01-21 | 威智医药有限公司 | 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法 |
US11040983B1 (en) | 2020-08-14 | 2021-06-22 | Almatica Pharma Llc | Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof |
WO2022035434A1 (en) | 2020-08-14 | 2022-02-17 | Almatica Pharma Llc | Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof |
WO2022147189A1 (en) * | 2020-12-30 | 2022-07-07 | Antares Pharma, Inc. | Varenicline prodrugs |
WO2022222019A1 (en) * | 2021-04-20 | 2022-10-27 | Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd | Total synthesis of varenicline |
CN113277993B (zh) * | 2021-06-06 | 2023-07-21 | 湖南第一师范学院 | 一种Tafamidis及其衍生物的合成方法 |
WO2023275413A2 (en) | 2021-12-23 | 2023-01-05 | Medichem, S.A. | Solid pharmaceutical formulations of varenicline |
EP4241775A1 (en) | 2022-03-11 | 2023-09-13 | Par Pharmaceutical, Inc. | Tablet comprising varenicline and process of preparation thereof |
US11602537B2 (en) | 2022-03-11 | 2023-03-14 | Par Pharmaceutical, Inc. | Varenicline compound and process of manufacture thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3471503A (en) * | 1967-05-05 | 1969-10-07 | Mcneilab Inc | 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols |
CH644116A5 (de) * | 1980-08-21 | 1984-07-13 | Hoffmann La Roche | Imidazolderivate. |
EP0853621A1 (en) † | 1995-09-22 | 1998-07-22 | Novo Nordisk A/S | Novel substituted azacyclic or azabicyclic compounds |
SI1044189T2 (sl) * | 1997-12-31 | 2015-05-29 | Pfizer Products Inc. | Z arilom kondenzirane azapoliciklične spojine |
US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
AU1918299A (en) * | 1998-02-23 | 1999-09-06 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
EP0955301A3 (en) * | 1998-04-27 | 2001-04-18 | Pfizer Products Inc. | 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors |
ID26700A (id) * | 1998-04-29 | 2001-02-01 | Pfizer Prod Inc | Senyawa-senyawa azapolisiklik yang bercampur dengan aril |
JP4676062B2 (ja) * | 1999-01-29 | 2011-04-27 | アボット・ラボラトリーズ | ニコチン性アセチルコリン受容体リガンドとしてのジアザ2環式誘導体 |
FR2788982B1 (fr) * | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
CN1509288A (zh) * | 2001-05-14 | 2004-06-30 | �Ʒ� | 5,8,14-三氮杂四环[10.3.1.02,11.04,9]-十六-2(11),3,5,7,9-五烯的柠檬酸盐 |
IL157933A0 (en) * | 2001-05-14 | 2004-03-28 | Pfizer Prod Inc | Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9] -hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
RU2004116311A (ru) * | 2001-11-29 | 2005-03-27 | Пфайзер Продактс Инк. (Us) | Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции |
CN1864663A (zh) * | 2001-11-30 | 2006-11-22 | 辉瑞产品公司 | 5,7,14-三氮杂四环[10.3.1.0(2,11).0(4,9)]-十六碳-2(11)3,5,7,9-五烯的药物组合物 |
DE60228478D1 (de) * | 2001-11-30 | 2008-10-02 | Pfizer Prod Inc | Aryl-annellierte azapolyzyklische verbindungen |
CA2533100A1 (en) * | 2003-07-21 | 2005-01-27 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
-
1998
- 1998-11-13 SI SI9830902T patent/SI1044189T2/sl unknown
- 1998-11-13 CN CNA2005100821428A patent/CN1715280A/zh active Pending
- 1998-11-13 DK DK98950274T patent/DK1044189T4/en active
- 1998-11-13 EP EP98950274.5A patent/EP1044189B2/en not_active Expired - Lifetime
- 1998-11-13 DE DE69839131.4T patent/DE69839131T3/de not_active Expired - Lifetime
- 1998-11-13 BR BRPI9814592-4A patent/BR9814592B1/pt not_active IP Right Cessation
- 1998-11-13 UA UA2000063807A patent/UA66825C2/uk unknown
- 1998-11-13 SG SG200203917A patent/SG102686A1/en unknown
- 1998-11-13 AU AU96416/98A patent/AU753389C/en not_active Expired
- 1998-11-13 PT PT98950274T patent/PT1044189E/pt unknown
- 1998-11-13 KR KR10-2000-7007379A patent/KR100408138B1/ko active IP Right Review Request
- 1998-11-13 JP JP2000527532A patent/JP3550359B2/ja not_active Expired - Lifetime
- 1998-11-13 NZ NZ504482A patent/NZ504482A/xx not_active IP Right Cessation
- 1998-11-13 EA EA200000592A patent/EA003190B1/ru not_active IP Right Cessation
- 1998-11-13 ES ES98950274.5T patent/ES2301210T5/es not_active Expired - Lifetime
- 1998-11-13 CA CA002316921A patent/CA2316921C/en not_active Expired - Lifetime
- 1998-11-13 BR BRPI9816186-5A patent/BR9816186B1/pt not_active IP Right Cessation
- 1998-11-13 TR TR2000/01840T patent/TR200001840T2/xx unknown
- 1998-11-13 ME MEP-2008-702A patent/ME00459B/me unknown
- 1998-11-13 US US09/402,010 patent/US6410550B1/en not_active Expired - Lifetime
- 1998-11-13 IL IL13672798A patent/IL136727A0/xx active Protection Beyond IP Right Term
- 1998-11-13 PL PL341824A patent/PL209404B1/pl unknown
- 1998-11-13 CN CNB988128195A patent/CN1324013C/zh not_active Expired - Lifetime
- 1998-11-13 AT AT98950274T patent/ATE386024T1/de active
- 1998-11-13 HU HU0100949A patent/HU230297B1/hu active Protection Beyond IP Right Term
- 1998-11-13 RS YUP-403/00A patent/RS50069B/sr unknown
- 1998-11-13 CZ CZ20002438A patent/CZ301925B6/cs not_active IP Right Cessation
- 1998-11-13 SK SK971-2000A patent/SK286886B6/sk not_active IP Right Cessation
- 1998-11-13 DE DE122008000038C patent/DE122008000038I1/de active Pending
- 1998-11-13 WO PCT/IB1998/001813 patent/WO1999035131A1/en active IP Right Grant
- 1998-11-13 EP EP05106853A patent/EP1659114A3/en not_active Withdrawn
- 1998-11-19 HN HN1998000177A patent/HN1998000177A/es unknown
- 1998-11-30 CO CO98070723A patent/CO4810373A1/es unknown
- 1998-11-30 PA PA19988463901A patent/PA8463901A1/es unknown
- 1998-12-15 GT GT199800200AK patent/GT199800200AA/es unknown
- 1998-12-15 GT GT199800200A patent/GT199800200A/es unknown
- 1998-12-17 AP APAP/P/1998/001422A patent/AP1170A/en active
- 1998-12-28 TW TW087121748A patent/TW513412B/zh not_active IP Right Cessation
- 1998-12-28 PE PE1998001286A patent/PE20000053A1/es not_active IP Right Cessation
- 1998-12-28 EG EG161298A patent/EG23816A/xx active
- 1998-12-29 AR ARP980106715A patent/AR017967A1/es active IP Right Grant
- 1998-12-29 ZA ZA9811911A patent/ZA9811911B/xx unknown
- 1998-12-30 MA MA25409A patent/MA26589A1/fr unknown
- 1998-12-30 MY MYPI98005949A patent/MY118163A/en unknown
- 1998-12-30 TN TNTNSN98237A patent/TNSN98237A1/fr unknown
- 1998-12-30 DZ DZ980307A patent/DZ2697A1/xx active
-
1999
- 1999-02-28 SA SA99191123A patent/SA99191123B1/ar unknown
-
2000
- 2000-05-26 IS IS5514A patent/IS5514A/is unknown
- 2000-06-12 IL IL136727A patent/IL136727A/en active Protection Beyond IP Right Term
- 2000-06-16 OA OA1200000175A patent/OA11428A/en unknown
- 2000-06-27 BG BG104561A patent/BG65058B1/bg unknown
- 2000-06-30 NO NO20003422A patent/NO319115B1/no not_active IP Right Cessation
- 2000-06-30 HR HR20000445A patent/HRP20000445B1/xx not_active IP Right Cessation
-
2001
- 2001-04-09 HK HK01102476A patent/HK1031878A1/xx not_active IP Right Cessation
-
2002
- 2002-02-13 US US10/075,843 patent/US6887884B2/en not_active Expired - Fee Related
- 2002-02-14 US US10/075,348 patent/US20020072524A1/en not_active Abandoned
- 2002-04-22 US US10/127,267 patent/US6951938B2/en not_active Expired - Lifetime
- 2002-04-23 US US10/131,278 patent/US6897310B2/en not_active Expired - Lifetime
-
2005
- 2005-06-07 HR HR20050506A patent/HRP20050506A2/hr not_active Application Discontinuation
-
2006
- 2006-11-17 NO NO2006016C patent/NO2006016I1/no not_active IP Right Cessation
-
2007
- 2007-07-17 US US11/778,890 patent/US20070275973A1/en not_active Abandoned
-
2008
- 2008-04-14 CY CY20081100397T patent/CY1107391T1/el unknown
- 2008-05-21 LU LU91442C patent/LU91442I2/fr unknown
- 2008-06-05 NL NL300355C patent/NL300355I2/nl unknown
- 2008-07-03 CY CY200800013C patent/CY2008013I1/el unknown
- 2008-07-21 FR FR08C0039C patent/FR08C0039I2/fr active Active
-
2016
- 2016-04-27 HU HUS1600018C patent/HUS1600018I1/hu unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101109389B1 (ko) * | 2010-04-30 | 2012-01-30 | 삼성전기주식회사 | 인쇄회로기판 및 그 제조방법 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100408138B1 (ko) | 아릴 융합된 아자폴리사이클릭 화합물 | |
DE60120366T2 (de) | Aryl-kondensierte azopolycyclische Verbindungen | |
KR100551183B1 (ko) | 1,3-치환 인덴 및 아릴-융합 아자폴리시클릭 화합물의제조 방법 | |
AU2002234836A1 (en) | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121030 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20131030 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20141030 Year of fee payment: 12 |
|
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J121 | Written withdrawal of request for trial | ||
FPAY | Annual fee payment |
Payment date: 20150930 Year of fee payment: 13 |
|
J121 | Written withdrawal of request for trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20150424 Effective date: 20151126 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
FPAY | Annual fee payment |
Payment date: 20161028 Year of fee payment: 14 |
|
J121 | Written withdrawal of request for trial | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017100001942; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001826; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170615 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100002368; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170726 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001823; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170615 Effective date: 20180411 Free format text: TRIAL NUMBER: 2016100002953; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160923 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001943; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001939; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001938; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001937; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2016100002944; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160923 Effective date: 20180411 Free format text: TRIAL NUMBER: 2016100002936; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160923 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001940; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001945; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2016100002948; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160923 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001941; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001322; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170426 Effective date: 20180411 Free format text: TRIAL NUMBER: 2016100002918; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160923 Effective date: 20180411 Free format text: TRIAL NUMBER: 2016100002956; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160923 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001944; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2016100002949; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160923 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001396; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170504 Effective date: 20180411 |
|
J121 | Written withdrawal of request for trial | ||
J122 | Written withdrawal of action (patent court) | ||
FPAY | Annual fee payment |
Payment date: 20180928 Year of fee payment: 16 |
|
J204 | Request for invalidation trial [patent] | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2019100000651; TRIAL DECISION FOR INVALIDATION REQUESTED 20190222 Effective date: 20190524 Free format text: TRIAL NUMBER: 2019100000653; TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20190222 Effective date: 20190524 |
|
J202 | Request for trial for correction [limitation] | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20190924 Year of fee payment: 17 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2019105000051; TRIAL DECISION FOR CORRECTION REQUESTED 20190527 Effective date: 20191007 |
|
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2018200004041; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180510 Effective date: 20191220 Free format text: TRIAL NUMBER: 2018200004058; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180510 Effective date: 20191220 |
|
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2019200004727; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20190621 Effective date: 20191220 |
|
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2018200004089; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180510 Effective date: 20191220 Free format text: TRIAL NUMBER: 2018200004102; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180510 Effective date: 20191220 Free format text: TRIAL NUMBER: 2018200004119; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180510 Effective date: 20191220 Free format text: TRIAL NUMBER: 2018200004065; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180510 Effective date: 20191220 Free format text: TRIAL NUMBER: 2018200004096; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180510 Effective date: 20191220 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2020130000025; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000028; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000011; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200113 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000017; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000022; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000019; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000021; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000016; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000018; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000015; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000024; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000027; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000010; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200113 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000020; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000023; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000026; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 |